• Center on Health Equity & Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Vowst as a Potential Option for Patients With Recurrent C Difficile Infections

Opinion
Video

The panelist discusses Vowst, an FDA-approved live microbiota therapeutic that works by introducing healthy donor-derived gut bacteria to restore microbiome diversity, distinguishing itself from traditional antibiotics in preventing recurrent Clostridioides difficile infections in adults who have completed antibiotic treatment.

Related Videos
Dr Arielle Kauvar
Dr Brian Koffman
1 expert in this video
1 expert in this video
Paula Rodríguez-Otero, MD, PhD
5 Experts are featured in this series.
5 experts are featured in this series.
5 experts in this video
5 experts in this video
Dr Brian Koffman
Related Content
© 2025 MJH Life Sciences
AJMC®
All rights reserved.